SABCS 2017: The latest in CDK inhibition in breast cancer

• Date : 05/12/2017
• 1    
  0

Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients

• Date : 05/12/2017
• 1    
  0

Acupuncture significantly reduces joint pain for breast cancer patients

• Date : 05/12/2017
• 1    
  0

Immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer

• Date : 05/12/2017
• 0    
  0

Individualising treatment of axillary nodes in breast cancer

• Date : 05/12/2017
• 0    
  0

The REACT trial: Celecoxib vs placebo for primary breast cancer

• Date : 05/12/2017
• 0    
  0

Temporary ovarian suppression

• Date : 05/12/2017
• 0    
  0

Positive advanced breast cancer

• Date : 05/12/2017
• 0    
  0

Adjuvant trastuzumab did not improve outcomes for patients

• Date : 05/12/2017
• 0    
  0

Increasing dose intensity of chemo may lower the risk of breast cancer

• Date : 05/12/2017
• 0    
  0

CDK 4/6 inhibitors for older women with HR-positive breast cancer

• Date : 05/12/2017
• 0    
  0

Acupuncture significantly reduces joint pain for breast cancer patients

• Date : 05/12/2017
• 0    
  0

Tandem duplicator phenotypes define 50% of triple negative breast cancers

• Date : 05/12/2017
• 0    
  0

Comparing adjuvant tamoxifen with ovarian function suppression

• Date : 05/12/2017
• 0    
  0

Telazoparib vs physicians choice for patients with mBRCA1 breast cancer

• Date : 05/12/2017
• 0    
  0

Updated genomic screening tool for life-time breast cancer risk

• Date : 05/12/2017
• 0    
  0

Low invasive breast cancer

• Date : 05/12/2017
• 0    
  0

How can scalp-cooling reduce chemotherapy induced hair loss?

• Date : 05/12/2017
• 0    
  0

Predicting late breast cancer recurrence with screening assays

• Date : 05/12/2017
• 0    
  0

Screening for clinical variables to predict late distance disease recurrence

• Date : 05/12/2017
• 0    
  0

Rationale and recruitment in the PARTNER trial

• Date : 05/12/2017
• 0    
  0

Anastrozole duration for post-menopausal breast cancer patients

• Date : 05/12/2017
• 0    
  0

Breast cancer therapy resistance mediated by FGFR amplification

• Date : 05/12/2017
• 0    
  0

PIII trial supports current standard 12-month

• Date : 05/12/2017
• 0    
  0

Temporary ovarian suppression

• Date : 05/12/2017
• 0    
  0

Two years of extended anastrazole therapy as effective as five

• Date : 05/12/2017
• 0    
  0

Reducing risk of breast cancer recurrence and death with increased dose density

• Date : 05/12/2017
• 0    
  0

The role of axiliary node dissection in modern breast cancer surgery

• Date : 05/12/2017
• 0    
  0

CDK 4/6 inhibitors for older women with HR-positive breast cancer

• Date : 05/12/2017
• 0    
  0

Telazoparib vs physicians choice for patients with mBRCA1 breast cancern

• Date : 05/12/2017
• 0    
  0

Postmenopausal women who lose weight may have reduced breast cancer risk

• Date : 05/12/2017
• 0    
  0

The significance of CEACAM 5 in metastases of triple negative breast cancer

• Date : 05/12/2017
• 0    
  0

Congrès ESMO 2026

• Date : 23/10/2026
• 51    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date : 10/12/2025
• 137    
  0

SABCS 2025 Symposium

• Date : 09/12/2025
• 5332    
  0

Congrès ESMO Asie 2025

• Date : 05/12/2025
• 306    
  0

17ᵉ Congrès Européen Multidisciplinaire sur le Cancer Urologique - EMUC25

• Date : 13/11/2025
• 465    
  0